bemiparin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
heparin derivatives including low molecular mass heparins 4840 9041-08-1

Description:

MoleculeDescription

Synonyms:

  • tinzaparin
  • ardeparin sodium
  • dalteparin sodium
  • tinzaparin sodium
  • bemiparin
  • bemiparin sodium
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
3.50 TU P
2.50 TU P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1994 FDA PFIZER INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary embolism 211.00 12.80 246 22911 101458 50480509
Hepatocellular injury 144.74 12.80 109 23048 25838 50556129
Drug ineffective 136.60 12.80 106 23051 819227 49762740
Toxic epidermal necrolysis 123.36 12.80 91 23066 20901 50561066
Acute kidney injury 120.91 12.80 299 22858 227759 50354208
Thrombocytopenia 106.22 12.80 201 22956 127472 50454495
Heparin-induced thrombocytopenia 94.97 12.80 43 23114 3922 50578045
General physical health deterioration 83.14 12.80 194 22963 142240 50439727
Cholestasis 78.42 12.80 76 23081 25325 50556642
Deep vein thrombosis 73.16 12.80 125 23032 73179 50508788
Needle issue 70.38 12.80 43 23114 7232 50574735
Anaemia 70.19 12.80 264 22893 252192 50329775
Drug intolerance 65.13 12.80 11 23146 219093 50362874
Arthralgia 62.85 12.80 65 23092 438637 50143330
Rheumatoid arthritis 58.39 12.80 11 23146 202539 50379428
Product dose omission issue 57.43 12.80 8 23149 183830 50398137
Neutropenic sepsis 54.68 12.80 48 23109 14099 50567868
Arthropathy 54.00 12.80 5 23152 157901 50424066
Drug reaction with eosinophilia and systemic symptoms 52.64 12.80 65 23092 28359 50553608
Biliary sepsis 51.42 12.80 18 23139 832 50581135
Rash maculo-papular 51.08 12.80 62 23095 26579 50555388
Blue toe syndrome 51.06 12.80 15 23142 391 50581576
Blood creatine increased 50.14 12.80 30 23127 4857 50577110
Arteriovenous fistula occlusion 47.65 12.80 14 23143 365 50581602
Therapeutic product effect decreased 47.35 12.80 4 23153 136046 50445921
Jaundice 46.65 12.80 59 23098 26370 50555597
Venous pressure jugular decreased 45.95 12.80 9 23148 35 50581932
Neutropenia 45.49 12.80 160 22997 147805 50434162
Abdominal discomfort 45.03 12.80 25 23132 231616 50350351
Hyperthyroidism 44.45 12.80 40 23117 12135 50569832
Melaena 44.32 12.80 58 23099 26806 50555161
Vessel puncture site bruise 43.92 12.80 13 23144 348 50581619
Dermatitis exfoliative 43.71 12.80 28 23129 5114 50576853
Sinusitis 43.67 12.80 12 23145 170546 50411421
Febrile neutropenia 43.34 12.80 120 23037 97547 50484420
Agranulocytosis 42.95 12.80 51 23106 21370 50560597
Gamma-glutamyltransferase increased 41.37 12.80 59 23098 29564 50552403
Glossodynia 41.33 12.80 3 23154 115566 50466401
Pituitary tumour 39.92 12.80 15 23142 850 50581117
Adrenal suppression 39.81 12.80 15 23142 857 50581110
Headache 39.38 12.80 111 23046 506424 50075543
Ovarian hyperstimulation syndrome 38.81 12.80 22 23135 3222 50578745
Thrombosis 38.08 12.80 81 23076 55752 50526215
Joint swelling 37.77 12.80 34 23123 245252 50336715
Systemic lupus erythematosus 37.71 12.80 9 23148 140613 50441354
Haematoma 37.19 12.80 57 23100 30453 50551514
Haemoglobin decreased 36.90 12.80 135 23022 127081 50454886
Alopecia 36.51 12.80 35 23122 245012 50336955
Blood loss anaemia 36.33 12.80 30 23127 8109 50573858
Drug hypersensitivity 36.08 12.80 37 23120 250973 50330994
Hypothalamo-pituitary disorder 35.71 12.80 13 23144 674 50581293
Body dysmorphic disorder 34.25 12.80 10 23147 255 50581712
Ascites 34.24 12.80 60 23097 35801 50546166
Activated partial thromboplastin time prolonged 33.71 12.80 26 23131 6376 50575591
Sepsis 33.57 12.80 135 23022 132790 50449177
Malignant neoplasm progression 33.53 12.80 87 23070 68037 50513930
Discomfort 33.17 12.80 5 23152 108375 50473592
Blood creatinine increased 32.23 12.80 92 23065 76068 50505899
Pancytopenia 32.21 12.80 98 23059 83932 50498035
Pyrexia 31.93 12.80 289 22868 379914 50202053
Perforation 31.43 12.80 13 23144 951 50581016
Abdominal wall haematoma 31.41 12.80 18 23139 2690 50579277
Treatment failure 31.14 12.80 12 23145 137625 50444342
Cytokine release syndrome 30.79 12.80 28 23129 8606 50573361
Depression 30.50 12.80 19 23138 165404 50416563
Abdominal wall haemorrhage 30.41 12.80 8 23149 137 50581830
Cardiac failure 30.39 12.80 90 23067 75950 50506017
Pneumothorax traumatic 29.48 12.80 8 23149 155 50581812
Pain 29.31 12.80 151 23006 578752 50003215
Fatigue 29.26 12.80 197 22960 707404 49874563
Epistaxis 28.77 12.80 79 23078 63875 50518092
Hyperkalaemia 28.54 12.80 66 23091 48023 50533944
Drug interaction 28.34 12.80 172 22985 199449 50382518
Wound 27.91 12.80 7 23150 105787 50476180
Cardiomyopathy acute 27.82 12.80 8 23149 193 50581774
Haematoma muscle 27.80 12.80 11 23146 717 50581250
Joint ankylosis 27.29 12.80 11 23146 753 50581214
Gastric antral vascular ectasia 27.18 12.80 10 23147 534 50581433
Gastrointestinal haemorrhage 26.70 12.80 84 23073 73237 50508730
Electrolyte imbalance 26.67 12.80 36 23121 17133 50564834
Intra-abdominal haemorrhage 26.41 12.80 15 23142 2205 50579762
Premature baby 26.31 12.80 37 23120 18300 50563667
Exposure during pregnancy 25.98 12.80 117 23040 120898 50461069
Pericarditis 25.58 12.80 3 23154 78686 50503281
Catheter site thrombosis 25.49 12.80 7 23150 142 50581825
Cerebral haemorrhage 25.48 12.80 45 23112 27007 50554960
Bronchopulmonary dysplasia 25.15 12.80 8 23149 274 50581693
Haemorrhagic erosive gastritis 25.15 12.80 8 23149 274 50581693
Bone marrow eosinophilic leukocyte count increased 25.03 12.80 5 23152 22 50581945
Psychiatric decompensation 25.02 12.80 12 23145 1246 50580721
Muscle haemorrhage 24.88 12.80 16 23141 2942 50579025
Musculoskeletal stiffness 24.75 12.80 14 23143 128467 50453500
Disease progression 24.70 12.80 98 23059 95768 50486199
Cholecystitis 24.53 12.80 31 23126 13840 50568127
Neoplasm progression 24.30 12.80 46 23111 29111 50552856
Fracture blisters 24.20 12.80 6 23151 80 50581887
Allergic hepatitis 24.03 12.80 5 23152 28 50581939
Feeling abnormal 23.71 12.80 14 23143 125478 50456489
Constipation 23.24 12.80 155 23002 185553 50396414
Renal tubular acidosis 22.77 12.80 12 23145 1522 50580445
Contraindicated product administered 22.49 12.80 21 23136 148937 50433030
Multiple organ dysfunction syndrome 22.46 12.80 62 23095 50275 50531692
Pleural effusion 22.39 12.80 85 23072 81369 50500598
Femoral neck fracture 22.34 12.80 22 23135 7468 50574499
Hepatitis cholestatic 22.13 12.80 20 23137 6097 50575870
Haemoptysis 22.13 12.80 41 23116 25532 50556435
Pneumobilia 22.07 12.80 6 23151 117 50581850
Retroperitoneal haemorrhage 21.93 12.80 14 23143 2542 50579425
Embolism 21.78 12.80 21 23136 6947 50575020
Erythema 21.29 12.80 127 23030 146287 50435680
International normalised ratio increased 21.11 12.80 55 23102 43097 50538870
Respiratory disorder 20.97 12.80 45 23112 31142 50550825
Granulomatous liver disease 20.83 12.80 9 23148 734 50581233
Foetal growth restriction 20.77 12.80 20 23137 6607 50575360
Therapeutic product effect incomplete 20.66 12.80 8 23149 91507 50490460
Thrombophlebitis 20.55 12.80 16 23141 3977 50577990
Hyperlipasaemia 20.33 12.80 8 23149 514 50581453
Eosinophilia 20.17 12.80 33 23124 18619 50563348
Caesarean section 20.16 12.80 30 23127 15609 50566358
Diarrhoea haemorrhagic 20.07 12.80 21 23136 7654 50574313
Leukopenia 19.84 12.80 72 23085 67456 50514511
Limbal swelling 19.77 12.80 4 23153 19 50581948
Cholestatic liver injury 19.68 12.80 12 23145 2009 50579958
Cardiac failure congestive 19.68 12.80 7 23150 84375 50497592
Impaired healing 19.64 12.80 4 23153 69782 50512185
Anaemia folate deficiency 19.52 12.80 6 23151 183 50581784
Diarrhoea 19.39 12.80 377 22780 588099 49993868
Phlebitis 19.33 12.80 18 23139 5702 50576265
Cerebral infarction 19.15 12.80 35 23122 21569 50560398
Hypersensitivity 19.08 12.80 44 23113 215117 50366850
Gastric ulcer 18.23 12.80 34 23123 21271 50560696
Haemangioma congenital 18.06 12.80 7 23150 432 50581535
Protein S decreased 17.99 12.80 4 23153 32 50581935
Alanine aminotransferase increased 17.89 12.80 84 23073 88275 50493692
Faecaloma 17.79 12.80 19 23138 7089 50574878
Protein C decreased 17.67 12.80 4 23153 35 50581932
Blood alkaline phosphatase increased 17.51 12.80 47 23110 37479 50544488
Acute generalised exanthematous pustulosis 17.45 12.80 21 23136 8917 50573050
Subcutaneous haematoma 17.38 12.80 10 23147 1505 50580462
Lordosis 17.27 12.80 6 23151 271 50581696
Maternal drugs affecting foetus 17.20 12.80 16 23141 5061 50576906
Intra-abdominal haematoma 17.13 12.80 10 23147 1547 50580420
Premature delivery 16.90 12.80 35 23122 23628 50558339
Chemotherapeutic drug level increased 16.82 12.80 5 23152 136 50581831
Cerebral haematoma 16.81 12.80 13 23144 3198 50578769
Haemolysis 16.71 12.80 17 23140 5999 50575968
Chest X-ray abnormal 16.67 12.80 14 23143 3871 50578096
Hypokalaemia 16.62 12.80 82 23075 87910 50494057
Haemorrhage 16.57 12.80 58 23099 53383 50528584
Visual acuity reduced transiently 16.54 12.80 5 23152 144 50581823
Gastrointestinal tract adenoma 16.32 12.80 6 23151 320 50581647
Skin warm 16.19 12.80 15 23142 4720 50577247
Varices oesophageal 16.17 12.80 12 23145 2777 50579190
Toxicity to various agents 16.12 12.80 47 23110 212452 50369515
Abdominal pain 16.07 12.80 172 22985 236056 50345911
Magnetic resonance imaging head abnormal 15.91 12.80 10 23147 1767 50580200
Blood cholesterol increased 15.89 12.80 3 23154 55212 50526755
Interstitial lung disease 15.88 12.80 57 23100 53119 50528848
Infantile haemangioma 15.82 12.80 4 23153 58 50581909
Ill-defined disorder 15.66 12.80 3 23154 54651 50527316
Infusion related reaction 15.58 12.80 34 23123 169523 50412444
Intracranial pressure increased 15.58 12.80 14 23143 4238 50577729
Persecutory delusion 15.50 12.80 11 23146 2376 50579591
Cardiac hypertrophy 15.43 12.80 8 23149 981 50580986
Acidosis 15.21 12.80 21 23136 10206 50571761
Normal newborn 15.21 12.80 17 23140 6674 50575293
Gastrointestinal disorder 14.62 12.80 13 23144 94443 50487524
Upper gastrointestinal haemorrhage 14.24 12.80 26 23131 16009 50565958
Stevens-Johnson syndrome 14.18 12.80 31 23126 21721 50560246
Renal pain 14.03 12.80 15 23142 5604 50576363
Vascular occlusion 13.92 12.80 7 23150 806 50581161
Bone marrow oedema 13.91 12.80 7 23150 807 50581160
Hypoaesthesia 13.89 12.80 23 23134 127234 50454733
Reticulocyte count increased 13.88 12.80 7 23150 811 50581156
Post procedural haematoma 13.86 12.80 8 23149 1212 50580755
CSF white blood cell count decreased 13.84 12.80 3 23154 21 50581946
Thrombosis prophylaxis 13.84 12.80 3 23154 21 50581946
Insomnia 13.76 12.80 38 23119 174827 50407140
Mucosal inflammation 13.70 12.80 45 23112 40097 50541870
Gestational diabetes 13.70 12.80 17 23140 7448 50574519
Clostridium difficile colitis 13.57 12.80 27 23130 17715 50564252
Foetal growth abnormality 13.49 12.80 3 23154 24 50581943
Humerus fracture 13.43 12.80 17 23140 7601 50574366
Red cell distribution width increased 13.37 12.80 18 23139 8541 50573426
Cholelithiasis 13.35 12.80 43 23114 37930 50544037
Rash 13.32 12.80 132 23025 437339 50144628
Anxiety disorder 13.27 12.80 12 23145 3661 50578306
Injection site erythema 13.27 12.80 9 23148 74927 50507040
Transaminases increased 13.14 12.80 35 23122 27789 50554178
Asthma 13.00 12.80 13 23144 89324 50492643
HER2 positive breast cancer 12.94 12.80 5 23152 306 50581661

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 188.97 13.67 77 21336 3403 29549711
General physical health deterioration 159.66 13.67 275 21138 102582 29450532
Appendicitis 126.56 13.67 79 21334 8700 29544414
Drug ineffective 103.88 13.67 68 21345 363102 29190012
Cardiogenic shock 97.85 13.67 93 21320 19097 29534017
Pulmonary embolism 96.27 13.67 187 21226 76347 29476767
Hepatocellular injury 77.52 13.67 86 21327 21157 29531957
Toxic epidermal necrolysis 75.93 13.67 79 21334 18074 29535040
Sepsis 66.05 13.67 240 21173 142442 29410672
Stress 63.39 13.67 78 21335 21412 29531702
Ascites 60.73 13.67 101 21312 36518 29516596
Thrombocytopenia 60.05 13.67 224 21189 134599 29418515
Heparin-induced thrombocytopenia 59.90 13.67 40 21373 4939 29548175
Lymph node calcification 59.04 13.67 15 21398 135 29552979
Acute kidney injury 58.28 13.67 359 21054 264908 29288206
Multiple organ dysfunction syndrome 54.96 13.67 133 21280 62983 29490131
Abdominal pain 51.45 13.67 214 21199 135143 29417971
Abdominal distension 49.13 13.67 105 21308 45806 29507308
Hyponatraemia 49.02 13.67 133 21280 67500 29485614
Toxicity to various agents 46.17 13.67 35 21378 173626 29379488
Drug abuse 43.22 13.67 4 21409 79879 29473235
Haemorrhage 37.11 13.67 93 21320 44979 29508135
Pulmonary sarcoidosis 36.82 13.67 14 21399 513 29552601
Aplasia 35.81 13.67 27 21386 4036 29549078
Death 32.29 13.67 133 21280 341951 29211163
Suspected product quality issue 31.29 13.67 9 21404 134 29552980
Neutropenia 30.52 13.67 181 21232 131530 29421584
Hepatic haematoma 29.44 13.67 11 21402 384 29552730
Ventricular fibrillation 29.41 13.67 46 21367 15787 29537327
Bronchial obstruction 29.26 13.67 16 21397 1375 29551739
Bronchial disorder 29.07 13.67 15 21398 1146 29551968
Product dose omission issue 28.84 13.67 17 21396 96366 29456748
Feeling abnormal 28.72 13.67 3 21410 54442 29498672
Dizziness 28.63 13.67 59 21354 189625 29363489
Splenic vein thrombosis 28.50 13.67 11 21402 420 29552694
Haematemesis 28.28 13.67 58 21355 24568 29528546
Peritoneal haematoma 27.96 13.67 7 21406 59 29553055
Mucosal inflammation 27.92 13.67 67 21346 31528 29521586
Febrile neutropenia 27.13 13.67 156 21257 112084 29441030
Cholestasis 26.64 13.67 55 21358 23407 29529707
Shock haemorrhagic 25.50 13.67 33 21380 9518 29543596
Cardiac failure congestive 25.13 13.67 12 21401 76569 29476545
Chondrocalcinosis 24.85 13.67 9 21404 287 29552827
Floppy infant 24.23 13.67 7 21406 106 29553008
Oesophagitis 24.06 13.67 36 21377 11887 29541227
Genitalia external ambiguous 23.75 13.67 8 21405 205 29552909
Septic shock 22.99 13.67 98 21315 62462 29490652
Metastatic malignant melanoma 22.84 13.67 15 21398 1800 29551314
Depression 22.80 13.67 17 21396 85130 29467984
Portal vein thrombosis 22.75 13.67 19 21394 3290 29549824
Mucosal disorder 22.71 13.67 14 21399 1506 29551608
Muscle haemorrhage 22.48 13.67 19 21394 3343 29549771
Hyperkalaemia 22.43 13.67 96 21317 61296 29491818
Haemorrhagic disorder 22.41 13.67 10 21403 553 29552561
Rash maculo-papular 21.99 13.67 52 21361 24237 29528877
Embolism 21.91 13.67 26 21387 6870 29546244
Congenital bladder anomaly 21.80 13.67 8 21405 265 29552849
Hypertrophic osteoarthropathy 21.61 13.67 6 21407 78 29553036
Lung cancer metastatic 21.10 13.67 16 21397 2411 29550703
Pancytopenia 21.01 13.67 117 21296 83051 29470063
Eosinophil percentage decreased 20.52 13.67 6 21407 95 29553019
Haematoma 20.26 13.67 49 21364 23163 29529951
Foetal hypokinesia 19.28 13.67 8 21405 370 29552744
Coagulation factor VII level decreased 19.26 13.67 6 21407 119 29552995
Klebsiella infection 19.01 13.67 25 21388 7324 29545790
Compartment syndrome 18.79 13.67 15 21398 2437 29550677
Jaundice cholestatic 18.76 13.67 19 21394 4207 29548907
Prothrombin time shortened 18.69 13.67 12 21401 1386 29551728
Neonatal respiratory depression 18.61 13.67 8 21405 404 29552710
Thrombocytosis 18.52 13.67 17 21396 3336 29549778
Pulmonary artery thrombosis 18.50 13.67 9 21404 606 29552508
Respiratory disorder neonatal 18.48 13.67 12 21401 1413 29551701
Bladder tamponade 17.73 13.67 8 21405 454 29552660
Insomnia 17.67 13.67 23 21390 88738 29464376
Pyrexia 17.23 13.67 298 21115 287324 29265790
Blood pressure diastolic increased 17.15 13.67 17 21396 3669 29549445
Haemolytic anaemia 16.98 13.67 27 21386 9392 29543722
Neutropenic infection 16.93 13.67 11 21402 1296 29551818
Cardiac flutter 16.75 13.67 12 21401 1658 29551456
Butterfly rash 16.30 13.67 5 21408 94 29553020
Wrong strength 16.15 13.67 5 21408 97 29553017
Epistaxis 16.00 13.67 77 21336 51627 29501487
Hypokalaemia 15.71 13.67 75 21338 50128 29502986
Lung disorder 15.65 13.67 53 21360 30309 29522805
Therapeutic product effect prolonged 15.40 13.67 6 21407 235 29552879
Abdominal sepsis 15.26 13.67 9 21404 893 29552221
Myositis 15.24 13.67 27 21386 10256 29542858
Hepatic cytolysis 15.15 13.67 24 21389 8323 29544791
Anxiety 15.14 13.67 24 21389 85341 29467773
Gamma-glutamyltransferase increased 14.97 13.67 48 21365 26689 29526425
Vomiting 14.96 13.67 226 21187 212034 29341080
Constipation 14.95 13.67 137 21276 114023 29439091
Myalgia 14.92 13.67 19 21394 74000 29479114
Malignant neoplasm progression 14.88 13.67 98 21315 73761 29479353
Product communication issue 14.81 13.67 5 21408 129 29552985
Therapeutic product effect incomplete 14.78 13.67 5 21408 39300 29513814
Respiratory tract infection 14.70 13.67 34 21379 15617 29537497
Reading disorder 14.68 13.67 7 21406 451 29552663
Cerebral haemorrhage 14.59 13.67 53 21360 31373 29521741
Large intestine perforation 14.54 13.67 22 21391 7334 29545780
Miosis 14.50 13.67 23 21390 7986 29545128
Penile necrosis 14.48 13.67 4 21409 51 29553063
Lower respiratory tract infection 14.31 13.67 47 21366 26455 29526659
Hyperthermia 14.28 13.67 25 21388 9405 29543709
Hepatitis cholestatic 14.17 13.67 21 21392 6872 29546242
Haemoglobin decreased 14.16 13.67 130 21283 108245 29444869
Leukopenia 14.15 13.67 78 21335 55125 29497989
Soft tissue sarcoma 14.13 13.67 4 21409 56 29553058
Lactic acidosis 14.03 13.67 51 21362 30196 29522918
Hospitalisation 13.90 13.67 8 21405 45980 29507134
Headache 13.77 13.67 72 21341 173935 29379179
Agranulocytosis 13.72 13.67 39 21374 20301 29532813

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary embolism 267.59 11.64 395 40971 145961 64311405
General physical health deterioration 234.82 11.64 448 40918 203977 64253389
Drug ineffective 198.90 11.64 150 41216 840097 63617269
Appendicolith 198.19 11.64 77 41289 3392 64453974
Hepatocellular injury 196.40 11.64 190 41176 45045 64412321
Toxic epidermal necrolysis 176.37 11.64 164 41202 37002 64420364
Acute kidney injury 149.28 11.64 626 40740 448614 64008752
Thrombocytopenia 145.11 11.64 391 40975 223410 64233956
Heparin-induced thrombocytopenia 137.91 11.64 79 41287 8400 64448966
Appendicitis 106.24 11.64 80 41286 13489 64443877
Sepsis 96.67 11.64 346 41020 229995 64227371
Cholestasis 94.93 11.64 130 41236 44742 64412624
Ascites 85.10 11.64 147 41219 61854 64395512
Cardiogenic shock 84.28 11.64 104 41262 32323 64425043
Toxicity to various agents 81.68 11.64 68 41298 363445 64093921
Multiple organ dysfunction syndrome 73.60 11.64 185 41181 101228 64356138
Drug intolerance 70.40 11.64 17 41349 187975 64269391
Arthralgia 68.87 11.64 111 41255 442149 64015217
Drug abuse 68.76 11.64 4 41362 132370 64324996
Anaemia 65.42 11.64 441 40925 378239 64079127
Product dose omission issue 63.11 11.64 23 41343 194724 64262642
Rash maculo-papular 61.28 11.64 109 41257 46917 64410449
Deep vein thrombosis 60.38 11.64 176 41190 105006 64352360
Neutropenia 57.33 11.64 304 41062 239320 64218046
Lymph node calcification 53.96 11.64 16 41350 303 64457063
Arthropathy 53.80 11.64 7 41359 120960 64336406
Therapeutic product effect decreased 52.96 11.64 6 41360 115345 64342021
Abdominal pain 51.64 11.64 360 41006 312015 64145351
Febrile neutropenia 51.13 11.64 247 41119 187410 64269956
Headache 50.92 11.64 172 41194 529295 63928071
Gamma-glutamyltransferase increased 49.10 11.64 101 41265 48409 64408957
Haematoma 48.84 11.64 98 41268 46152 64411214
Neutropenic sepsis 48.57 11.64 67 41299 23205 64434161
Malignant neoplasm progression 48.50 11.64 171 41195 112700 64344666
Hyperkalaemia 45.87 11.64 156 41210 100973 64356393
Depression 45.32 11.64 31 41335 183260 64274106
Embolism 45.00 11.64 47 41319 12188 64445178
Pancytopenia 44.47 11.64 196 41170 143113 64314253
Constipation 44.37 11.64 275 41091 229062 64228304
Sinusitis 44.36 11.64 19 41347 145909 64311457
Abdominal discomfort 43.55 11.64 32 41334 182290 64275076
Drug reaction with eosinophilia and systemic symptoms 42.60 11.64 102 41264 54115 64403251
Blood loss anaemia 41.76 11.64 48 41318 13844 64443522
Abdominal distension 41.72 11.64 146 41220 95848 64361518
Epistaxis 41.58 11.64 148 41218 97983 64359383
Cardiac failure congestive 41.32 11.64 16 41350 130564 64326802
Feeling abnormal 41.25 11.64 17 41349 133585 64323781
Blue toe syndrome 40.88 11.64 15 41351 563 64456803
Agranulocytosis 40.36 11.64 81 41285 38148 64419218
Haemoglobin decreased 40.32 11.64 238 41128 194825 64262541
Biliary sepsis 39.53 11.64 19 41347 1409 64455957
Joint swelling 39.50 11.64 48 41318 215334 64242032
Haemorrhage 39.19 11.64 126 41240 79225 64378141
Rheumatoid arthritis 39.03 11.64 29 41337 164265 64293101
Hyperthyroidism 38.93 11.64 53 41313 18126 64439240
Jaundice 38.90 11.64 92 41274 48420 64408946
Muscle haemorrhage 38.68 11.64 31 41335 5722 64451644
Pyrexia 38.58 11.64 536 40830 558108 63899258
Blood creatine increased 38.55 11.64 36 41330 8156 64449210
Melaena 38.11 11.64 97 41269 53451 64403915
Arteriovenous fistula occlusion 37.92 11.64 14 41352 535 64456831
Cerebral haemorrhage 37.88 11.64 94 41272 50996 64406370
Shock haemorrhagic 37.56 11.64 50 41316 16741 64440625
Vessel puncture site bruise 37.55 11.64 13 41353 411 64456955
Venous pressure jugular decreased 36.40 11.64 9 41357 82 64457284
Hepatitis cholestatic 34.87 11.64 41 41325 12114 64445252
Ovarian hyperstimulation syndrome 34.60 11.64 22 41344 2823 64454543
Aplasia 33.58 11.64 31 41335 6922 64450444
Musculoskeletal stiffness 32.98 11.64 19 41347 123187 64334179
Discomfort 32.95 11.64 6 41360 80872 64376494
Treatment failure 32.75 11.64 17 41349 116799 64340567
Hyponatraemia 32.60 11.64 184 41182 148155 64309211
Therapeutic product effect incomplete 32.21 11.64 13 41353 103469 64353897
Pituitary tumour 31.48 11.64 15 41351 1091 64456275
Pulmonary sarcoidosis 31.17 11.64 15 41351 1116 64456250
Body dysmorphic disorder 31.14 11.64 10 41356 249 64457117
Dizziness 31.12 11.64 156 41210 430007 64027359
Mucosal inflammation 30.56 11.64 99 41267 62485 64394881
Thrombosis 30.31 11.64 107 41259 70535 64386831
Neoplasm progression 29.97 11.64 75 41291 40889 64416477
Haematemesis 29.24 11.64 81 41285 46918 64410448
Systemic lupus erythematosus 29.07 11.64 7 41359 77605 64379761
Adrenal suppression 28.89 11.64 15 41351 1312 64456054
Phlebitis 28.86 11.64 30 41336 7736 64449630
Diarrhoea 28.77 11.64 635 40731 722069 63735297
Glossodynia 28.15 11.64 4 41362 64692 64392674
Haematoma muscle 27.28 11.64 16 41350 1777 64455589
Fatigue 27.07 11.64 329 41037 748401 63708965
Thrombophlebitis 26.90 11.64 25 41341 5629 64451737
Suspected product quality issue 26.60 11.64 9 41357 265 64457101
Dermatitis exfoliative 26.56 11.64 33 41333 10319 64447047
Drug hypersensitivity 26.55 11.64 72 41294 237743 64219623
Gastrointestinal haemorrhage 26.40 11.64 160 41206 132152 64325214
Hypothalamo-pituitary disorder 26.23 11.64 13 41353 1031 64456335
Insomnia 25.97 11.64 55 41311 197781 64259585
Hepatic haematoma 25.95 11.64 12 41354 816 64456550
Blood alkaline phosphatase increased 25.67 11.64 87 41279 56192 64401174
Lung cancer metastatic 25.66 11.64 19 41347 3121 64454245
Intra-abdominal haemorrhage 25.58 11.64 21 41345 4010 64453356
Bronchial obstruction 25.54 11.64 17 41349 2357 64455009
Intentional overdose 25.34 11.64 13 41353 89931 64367435
Peritonitis 25.20 11.64 52 41314 24971 64432395
Bronchial disorder 24.84 11.64 16 41350 2099 64455267
Splenic vein thrombosis 24.55 11.64 11 41355 695 64456671
Needle issue 24.51 11.64 30 41336 9242 64448124
Alopecia 24.41 11.64 43 41323 165647 64291719
Abdominal wall haematoma 24.37 11.64 21 41345 4284 64453082
Retroperitoneal haemorrhage 24.08 11.64 22 41344 4846 64452520
Infusion related reaction 23.94 11.64 43 41323 164424 64292942
Limbal swelling 23.93 11.64 5 41361 19 64457347
Activated partial thromboplastin time prolonged 23.91 11.64 35 41331 12796 64444570
Pneumothorax traumatic 23.89 11.64 8 41358 228 64457138
Hypersensitivity 23.84 11.64 57 41309 196395 64260971
Cardiomyopathy acute 23.70 11.64 8 41358 234 64457132
Joint ankylosis 23.65 11.64 11 41355 758 64456608
Portal vein thrombosis 23.61 11.64 22 41344 4969 64452397
Haemolysis 23.36 11.64 32 41334 11007 64446359
Bone marrow eosinophilic leukocyte count increased 23.35 11.64 5 41361 22 64457344
Clostridium difficile colitis 23.33 11.64 53 41313 27170 64430196
Therapeutic response decreased 23.25 11.64 3 41363 52185 64405181
Death 23.24 11.64 198 41168 482507 63974859
Gastric antral vascular ectasia 23.13 11.64 11 41355 797 64456569
Nasal congestion 23.10 11.64 5 41361 59653 64397713
Oesophagitis 23.03 11.64 46 41320 21584 64435782
Klebsiella infection 22.99 11.64 35 41331 13246 64444120
Hepatic cytolysis 22.89 11.64 36 41330 14013 64443353
Hypokalaemia 22.80 11.64 145 41221 121758 64335608
Compartment syndrome 22.66 11.64 20 41346 4212 64453154
Septic shock 22.64 11.64 130 41236 105307 64352059
Subcutaneous haematoma 22.51 11.64 16 41350 2467 64454899
Gait disturbance 22.47 11.64 48 41318 172107 64285259
Perforation 22.23 11.64 12 41354 1136 64456230
Fracture blisters 22.19 11.64 6 41360 80 64457286
Ventricular fibrillation 22.19 11.64 48 41318 23812 64433554
Peritoneal haematoma 22.01 11.64 7 41359 169 64457197
Haemolytic anaemia 21.93 11.64 38 41328 16015 64441351
Allergic hepatitis 21.91 11.64 5 41361 31 64457335
Wound 21.62 11.64 11 41355 76466 64380900
Hyperthermia 21.49 11.64 37 41329 15513 64441853
Catheter site thrombosis 21.23 11.64 7 41359 190 64457176
Leukopenia 21.20 11.64 124 41242 101118 64356248
Asthma 21.10 11.64 18 41348 95207 64362159
Chondrocalcinosis 21.08 11.64 10 41356 720 64456646
Cytokine release syndrome 20.64 11.64 43 41323 20786 64436580
Thrombocytosis 20.30 11.64 24 41342 7132 64450234
Reading disorder 20.06 11.64 10 41356 803 64456563
Hypertrophic osteoarthropathy 19.88 11.64 6 41360 121 64457245
Abdominal wall haemorrhage 19.31 11.64 8 41358 417 64456949
Upper gastrointestinal haemorrhage 19.30 11.64 58 41308 35162 64422204
Myalgia 19.26 11.64 46 41320 158571 64298795
Eosinophil percentage decreased 19.07 11.64 7 41359 263 64457103
Pulmonary artery thrombosis 18.98 11.64 11 41355 1195 64456171
Retroperitoneal haematoma 18.96 11.64 19 41347 4692 64452674
Suicide attempt 18.93 11.64 11 41355 70996 64386370
Livedo reticularis 18.86 11.64 17 41349 3680 64453686
Pulmonary infarction 18.82 11.64 16 41350 3206 64454160
Pleural effusion 18.63 11.64 142 41224 126417 64330949
Neutropenic infection 18.60 11.64 13 41353 1952 64455414
Ill-defined disorder 18.53 11.64 3 41363 44049 64413317
Haemorrhagic erosive gastritis 18.40 11.64 8 41358 470 64456896
Hospitalisation 18.20 11.64 13 41353 75194 64382172
Pain 18.18 11.64 248 41118 553263 63904103
Psoriatic arthropathy 18.09 11.64 3 41363 43278 64414088
Lung disorder 18.04 11.64 82 41284 60618 64396748
Dysgraphia 17.79 11.64 16 41350 3455 64453911
Metastatic malignant melanoma 17.74 11.64 14 41352 2527 64454839
Bladder tamponade 17.65 11.64 8 41358 519 64456847
Intracranial pressure increased 17.49 11.64 22 41344 6967 64450399
Pneumobilia 17.44 11.64 6 41360 186 64457180
Stress 17.42 11.64 81 41285 60453 64396913
Basilar artery occlusion 17.17 11.64 6 41360 195 64457171
Engraftment syndrome 17.11 11.64 10 41356 1103 64456263
Cerebral haematoma 17.00 11.64 22 41344 7163 64450203
Coagulation factor VII level decreased 16.94 11.64 6 41360 203 64457163
Acute polyneuropathy 16.66 11.64 7 41359 378 64456988
Pain in jaw 16.65 11.64 3 41363 40752 64416614
Femoral neck fracture 16.55 11.64 24 41342 8700 64448666
Rectal haemorrhage 16.54 11.64 81 41285 61736 64395630
Injection site pain 16.32 11.64 29 41337 111379 64345987
Hypovolaemic shock 16.30 11.64 26 41340 10240 64447126
Transaminases increased 16.17 11.64 64 41302 44530 64412836
Antinuclear antibody positive 16.16 11.64 20 41346 6230 64451136
Treatment noncompliance 16.13 11.64 4 41362 43478 64413888
International normalised ratio increased 15.95 11.64 96 41270 79071 64378295
Anaemia folate deficiency 15.89 11.64 6 41360 244 64457122
Varices oesophageal 15.88 11.64 18 41348 5112 64452254
Vomiting 15.87 11.64 464 40902 550653 63906713
Overdose 15.85 11.64 51 41315 159515 64297851
Febrile bone marrow aplasia 15.84 11.64 27 41339 11228 64446138
Erysipelas 15.81 11.64 24 41342 9057 64448309
Alanine aminotransferase increased 15.70 11.64 147 41219 138884 64318482
Intentional product misuse 15.61 11.64 14 41352 72281 64385085
Cardiac failure 15.47 11.64 141 41225 132232 64325134
Adverse drug reaction 15.35 11.64 5 41361 45459 64411907
Penile necrosis 15.34 11.64 4 41362 46 64457320
Myositis 15.29 11.64 33 41333 16344 64441022
Balance disorder 15.06 11.64 19 41347 83907 64373459
Weight increased 15.03 11.64 78 41288 213270 64244096
Haemorrhagic disorder 15.01 11.64 10 41356 1389 64455977
Injection site erythema 14.95 11.64 14 41352 70786 64386580
Exposure during pregnancy 14.90 11.64 93 41273 77582 64379784
Mobility decreased 14.82 11.64 20 41346 85820 64371546
International normalised ratio decreased 14.81 11.64 21 41345 7457 64449909
Erythema 14.71 11.64 184 41182 186886 64270480
Influenza like illness 14.50 11.64 11 41355 61691 64395675
Blood cholesterol increased 14.46 11.64 7 41359 50059 64407307
Mean cell volume increased 14.44 11.64 17 41349 5029 64452337
Peripheral swelling 14.44 11.64 77 41289 209076 64248290
Cholecystitis 14.41 11.64 36 41330 19600 64437766
Lordosis 14.30 11.64 6 41360 323 64457043
Wrong strength 14.30 11.64 5 41361 163 64457203
Granulocyte count increased 14.25 11.64 8 41358 818 64456548
Magnetic resonance imaging head abnormal 14.13 11.64 12 41354 2400 64454966
Protein C decreased 14.12 11.64 4 41362 64 64457302
Viral infection 14.05 11.64 3 41363 36137 64421229
Psychiatric decompensation 13.91 11.64 12 41354 2451 64454915
Chemotherapeutic drug level increased 13.91 11.64 6 41360 346 64457020
Jaundice cholestatic 13.82 11.64 22 41344 8648 64448718
Pain in extremity 13.81 11.64 126 41240 302959 64154407
Migraine 13.70 11.64 12 41354 62665 64394701
Drug interaction 13.65 11.64 316 41050 361767 64095599
Influenza 13.65 11.64 30 41336 106501 64350865
Drug resistance 13.47 11.64 3 41363 35099 64422267
Loss of personal independence in daily activities 13.42 11.64 16 41350 72438 64384928
Lactic acidosis 13.36 11.64 76 41290 61334 64396032
Respiratory disorder 13.23 11.64 52 41314 36059 64421307
Duodenal ulcer perforation 13.21 11.64 3 41363 34622 64422744
Unevaluable event 13.20 11.64 8 41358 50481 64406885
Sudden hearing loss 13.20 11.64 10 41356 1700 64455666
Staphylococcal scalded skin syndrome 13.17 11.64 6 41360 394 64456972
Injury 13.13 11.64 10 41356 55982 64401384
Blood creatinine increased 13.11 11.64 139 41227 135643 64321723
Thrombosis prophylaxis 13.09 11.64 3 41363 19 64457347
Suicidal ideation 13.08 11.64 14 41352 66528 64390838
Mental status changes 13.02 11.64 12 41354 61150 64396216
Disseminated intravascular coagulation 13.02 11.64 48 41318 32300 64425066
Respiratory distress 12.89 11.64 67 41299 52264 64405102
Visual acuity reduced transiently 12.87 11.64 5 41361 220 64457146
Protein S decreased 12.84 11.64 4 41362 90 64457276
Hyperlipasaemia 12.76 11.64 8 41358 1002 64456364
Gastrointestinal stoma output increased 12.68 11.64 5 41361 229 64457137
Eosinophilia 12.50 11.64 53 41313 38023 64419343
CSF white blood cell count decreased 12.48 11.64 3 41363 24 64457342
Post procedural pulmonary embolism 12.46 11.64 5 41361 240 64457126
Electrolyte imbalance 12.38 11.64 40 41326 25203 64432163
Prostatitis Escherichia coli 12.37 11.64 3 41363 25 64457341
IIIrd nerve disorder 12.37 11.64 4 41362 102 64457264
Superior vena cava syndrome 12.30 11.64 8 41358 1067 64456299
Injection site bruising 12.28 11.64 4 41362 36369 64420997
Haemoptysis 12.22 11.64 63 41303 48985 64408381
Swelling 12.19 11.64 57 41309 160161 64297205
Gastrointestinal tract adenoma 12.18 11.64 6 41360 470 64456896
Throat irritation 12.15 11.64 3 41363 32708 64424658
Soft tissue sarcoma 12.12 11.64 4 41362 109 64457257
Emotional distress 12.10 11.64 4 41362 36034 64421332
HER2 positive breast cancer 12.04 11.64 5 41361 262 64457104
Therapy cessation 12.03 11.64 3 41363 32486 64424880
Nasopharyngitis 12.02 11.64 75 41291 195998 64261368
Faecaloma 11.97 11.64 22 41344 9706 64447660
Renal tubular acidosis 11.96 11.64 12 41354 2967 64454399
Malnutrition 11.93 11.64 33 41333 19092 64438274
Interstitial lung disease 11.87 11.64 105 41261 97627 64359739
Intra-abdominal haematoma 11.87 11.64 11 41355 2468 64454898
Fall 11.85 11.64 192 41174 416634 64040732
Reticulocyte count increased 11.72 11.64 8 41358 1156 64456210
Gastrointestinal disorder 11.71 11.64 25 41341 89684 64367682
Gastrointestinal ulcer perforation 11.71 11.64 3 41363 32 64457334

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AB10 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Heparin group
ATC B01AB12 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Heparin group
FDA CS M0010191 Heparin, Low-Molecular-Weight
FDA EPC N0000175586 Low Molecular Weight Heparin
MeSH PA D000925 Anticoagulants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D005343 Fibrinolytic Agents
MeSH PA D006401 Hematologic Agents
CHEBI has role CHEBI:50249 anticoagulants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pulmonary embolism indication 59282003 DOID:9477
Deep venous thrombosis indication 128053003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10,000IU/0.4ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 DISCN INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
10,000IU/ML (10,000IU/ML) FRAGMIN PFIZER N020287 Jan. 30, 1998 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
12,500IU/0.5ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
15,000IU/0.6ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
18,000IU/0.72ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
2,500IU/0.2ML (12,500IU/ML) FRAGMIN PFIZER N020287 Dec. 22, 1994 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
5,000IU/0.2ML (25,000IU/ML) FRAGMIN PFIZER N020287 March 18, 1996 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
7,500 IU/0.75ML FRAGMIN PFIZER N020287 April 4, 2002 DISCN INJECTABLE INJECTION May 16, 2022 NEW PATIENT POPULATION
7,500IU/0.3ML (25,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
95,000IU/3.8ML (25,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
95,000IU/9.5ML (10,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 DISCN INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

IDSource
PUE0TO3XDR UNII
4020894 VANDF
4021054 VANDF
4021237 VANDF
4024199 VANDF
C0916062 UMLSCUI
CHEBI:28304 CHEBI
CHEMBL3707365 ChEMBL_ID
772 PUBCHEM_CID
DB09258 DRUGBANK_ID
CHEMBL4650299 ChEMBL_ID
CHEMBL1201414 ChEMBL_ID
CHEMBL1201448 ChEMBL_ID
CHEMBL1201460 ChEMBL_ID
CHEMBL2108806 ChEMBL_ID
C411345 MESH_SUPPLEMENTAL_RECORD_UI
C093450 MESH_SUPPLEMENTAL_RECORD_UI
6846 IUPHAR_LIGAND_ID
9005-49-6 SECONDARY_CAS_RN
DB06822 DRUGBANK_ID
104466 RXNORM
15471 MMSL
4531 MMSL
d04659 MMSL
005078 NDDF
007911 NDDF
008338 NDDF
108987000 SNOMEDCT_US
108990006 SNOMEDCT_US
350469004 SNOMEDCT_US
395908006 SNOMEDCT_US
410964003 SNOMEDCT_US
410965002 SNOMEDCT_US
410967005 SNOMEDCT_US
412608008 SNOMEDCT_US
D000078222 MESH_DESCRIPTOR_UI
D017985 MESH_DESCRIPTOR_UI
6985 INN_ID
5688 INN_ID
6764 INN_ID
7501 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0195 INJECTION 2500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0196 INJECTION 5000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0206 INJECTION 7500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0217 INJECTION 10000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0220 INJECTION 12500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0223 INJECTION 15000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0228 INJECTION 18000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0232 INJECTION 25000 [iU] SUBCUTANEOUS NDA 28 sections